 The Tuberculosis Trials Consortium TBTC phase 3 treatment trial, Study 31, will investigate the efficacy and safety of daily rifapentine 1200 mg daily with or without moxifloxacin as part of multidrug treatment regimens for drug-sensitive pulmonary TB. The proposed study Study 31 PKPD will examine the population pharmacokinetics and pharmacodynamics PKPD of high-dose daily rifapentine with and without moxifloxacin given for 17 weeks. Two different PK sampling procedures are required for the population PKPD assessments involving rifapentine and moxifloxacin: 1 intensive sampling of 6 samplesparticipant on one occasion plus subsequent sparse sampling for a subset of Study 31 participants who are invited to co-enroll in Study 31 PKPD; and 2 sparse sampling of 2-3 samplesparticipant for all other Study 31 trial participants these data will be collected as part of the Study 31 treatment protocol. Herein, we describe the PK sampling to be conducted among those Study 31 participants who are co-enrolled to Study 31 PKPD n60. Intensive PK sampling is needed in some participants to estimate the population PK model parameters with no bias and satisfactory precision relative standard error 20. PK and outcomes data from all participants in Study 31 will be merged to build the population PKPD models to evaluate PKPD parameters. Details regarding these planned analyses are also provided in this Study 31 PKPD protocol. 